About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

BrightPath Biotherapeutics Co., Ltd.(4594) Summary

4594
TSE Growth
BrightPath Biotherapeutics Co., Ltd.
37
JPY
+2
(+5.71%)
Apr 10, 11:26 am JST
0.25
USD
Apr 9, 10:26 pm EDT
Result
PTS
outside of trading hours
36.8
Apr 10, 11:28 am JST
Summary Chart Historical News Financial Result
PER
PBR
2.98
Yield
ー%
Margin Trading Ratio
6.24
Stock Price
Apr 10, 2025
Opening Apr 10, 9:00 am
37 JPY 0.25 USD
Previous Close Apr 9
35 JPY 0.24 USD
High Apr 10, 9:03 am
38 JPY 0.25 USD
Low Apr 10, 9:27 am
35 JPY 0.23 USD
Volume
799,600
Trading Value
0.03B JPY 0.20M USD
VWAP
36.52 JPY 0.25 USD
Minimum Trading Value
3,700 JPY 25 USD
Market Cap
3.31B JPY 0.02B USD
Number of Trades
90
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
Mid
1-Year Average
218
1-Year High Jul 8, 2024
4,802
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 1,001,800 8,343,900 8.33
Mar 28, 2025 1,001,800 8,164,300 8.15
Mar 21, 2025 1,501,800 8,331,200 5.55
Mar 14, 2025 1,501,800 8,499,800 5.66
Mar 7, 2025 1,496,000 8,562,700 5.72
Company Profile
BrightPath Biotherapeutics Co., Ltd. is a biotech venture originating from Kurume University, focusing on cancer immunotherapy using NKT cells and antibody drugs.
Sector
Pharmaceuticals
BrightPath Biotherapeutics Co., Ltd. is a drug discovery venture specializing in the development of cancer immunotherapy drugs, originating from Kurume University. The company has multiple pipelines ranging from exploratory research to early clinical trial stages, with a business model that generates revenue by licensing out to domestic and international pharmaceutical companies for late-stage clinical trials and beyond. Major development pipelines include iPS cell-derived NKT cell therapy, CAR-T cell therapy, antibody drugs, and personalized neoantigen vaccines. Notably, in the field of iPS cell-derived NKT cell therapy, the company exercised its option rights in November 2022 to acquire an exclusive development, manufacturing, and sales license from RIKEN, and is conducting the world's first clinical trial using iPS-NKT cells for head and neck cancer. Additionally, the company is advancing the development of CAR-T cell therapy for solid tumors. BrightPath Biotherapeutics is also developing antibody drugs targeting molecules that suppress cancer immunity, aiming to innovate cancer treatment through multiple approaches.